Endocr Metab Immune Disord Drug Targets. 2024 Jul 22. doi: 10.2174/0118715303309437240703114340. Online ahead of print.
ABSTRACT
INTRODUCTION: We present an unusual case of a 28-year-old rheumatologic male patient who developed eosinophilia while he was on etanercept therapy first and then on golimumab.
CASE REPRESENTATION: Although eosinophilia is rarely reported in the literature as a side-effect of various Tumor Necrosis Factor-alpha [TNF-alpha] antagonists, it represents a riddle about the future treatments of these patients since the persistence of therapy might lead to the onset of dermatologic or visceral eosinophilic complications in such patients.
CONCLUSION: Furthermore, the pathogenesis of eosinophilia is still unknown, and all the proposed hypotheses do not explain the eosinophilic proliferation in certain subjects.
PMID:39041261 | DOI:10.2174/0118715303309437240703114340
